A phase I study of hepatic arterial infusion (HAI) of irinotecan in patients with inoperable liver metastases of colorectal cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 3714-3714 ◽  
Author(s):  
T. J. Vogl ◽  
K. Eichler ◽  
M. G. Mack ◽  
J. O. Balzer ◽  
C. Herzog ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Phase I ◽  
Liver Metastases ◽  
Phase I Study ◽  
Hepatic Arterial Infusion ◽  
Arterial Infusion

Phase I/II study of irinotecan, UFT, and leucovorin with hepatic arterial infusion in colorectal cancer patients with unresectable liver metastases: Preliminary results

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14549-14549
Author(s):  
T. Yamaguchi ◽  
H. Matsumoto ◽  
K. Takahashi ◽  
M. Yasutome ◽  
T. Mori
Keyword(s):  
Colorectal Cancer ◽  
Phase I ◽  
Liver Metastases ◽  
Phase Ii ◽  
Phase I Study ◽  
Phase Ii Study ◽  
Hepatic Arterial Infusion ◽  
Arterial Infusion ◽  
Unresectable Liver Metastases ◽  
Colorectal Cancer Patients

14549 Background: To determine the maximum-tolerated dose (MTD) and to evaluate the efficacy and tolerability of combination chemotherapy of irinotecan (CPT-11), UFT and leucovorin (LV) with hepatic arterial infusion (HAI) in colorectal cancer patients with unresectable liver metastases. Methods: Patients who had unresectable liver metastases from colorectal cancer were treated concurrently with intravenous CPT-11 on day1 of each 14-day treatment cycle with dose escalation, with orally UFT and LV on day 1–7 of each cycle, and with HAI of 5-FU on day 8–14 of each cycle. The primary objective of this phase I study was to determine the MTD of biweekly intravenous CPT-11 and UFT/LV with HAI of 5-FU. In the phase II study, the primary endpoint was to determine the response rate. Results: In the phase I study, the recommended dose of CPT-11 for phase II study was 140 mg/m2 combined with UFT 300 mg/m2/day, LV 75 mg/body/day and 5-FU 2,000 mg/body/week. Sixteen patients were enrolled onto the phase II study. The six patients treated at the recommended dose during the phase I study also included in the phase II analysis (n = 22). Median number of liver metastases was 12 (range, 3 to 35). Median size of maximum diameter was 6.3 cm (range, 2.0 to 12.0 cm). The most common adverse event was neutropenia. The complete and partial response rate totaled 81.8%. Median survival time has not been reached yet. Eleven patients (50.0%) were ultimately able to undergo liver resection. Conclusions: The combination chemotherapy of CPT-11 and UFT/LV with HAI was safe, well tolerate and effective in current population of the patients with unresectable liver metastases from colorectal cancer. Updated toxicity and response data will be available in the spring of 2007. No significant financial relationships to disclose.

Hepatic Arterial Infusion with Irinotecan in Patients with Liver Metastases of Colorectal Cancer: Results of an Extended Phase I Study

Chemotherapy ◽  
2013 ◽  
Vol 59 (1) ◽  
pp. 66-73 ◽  
Author(s):  
K. Eichler ◽  
T. Dufas ◽  
R. Hammerstingl ◽  
T. Gruber-Rouh ◽  
T.J. Vogl ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Phase I ◽  
Liver Metastases ◽  
Phase I Study ◽  
Hepatic Arterial Infusion ◽  
Arterial Infusion ◽  
Extended Phase

A phase I study of hepatic arterial infusion (HAI) of irinotecan in patients with inoperable liver metastases of colorectal cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 3714-3714
Author(s):  
T. J. Vogl ◽  
K. Eichler ◽  
M. G. Mack ◽  
J. O. Balzer ◽  
C. Herzog ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Phase I ◽  
Liver Metastases ◽  
Phase I Study ◽  
Hepatic Arterial Infusion ◽  
Arterial Infusion

Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer

2011 ◽  
Vol 47 (18) ◽  
pp. 2681-2690 ◽  
Author(s):  
M. Bouchahda ◽  
F. Lévi ◽  
R. Adam ◽  
P. Rougier
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Hepatic Arterial Infusion ◽  
Arterial Infusion
Sign in / Sign up

Export Citation Format

Share Document